Cannabis Exposure During Pregnancy Tied to Mental Health Problems in Early Adolescence
Prenatal cannabis exposure was associated with persisting vulnerability to psychopathology throughout early adolescence.
PPD Screening and Treatment: Is There Room for Improvement? A New Study at Mass General Brigham
Announcing a new CWMH study on postpartum depression screening and treatment outcomes at Mass General Brigham.
Risk Factors for Postpartum Depression: Family History of Psychiatric Illness
Family history of psychiatric illness was associated a twofold increased risk for postpartum depression.
August 22-29, 2022: Other News on the Web
Every week, there are so many important and interesting articles related to the care of women. While these articles may not fall under the umbrella of reproductive psychiatry, much of this information affects the women we care for.
FDA Accepts New Drug Application for Fezolinetant, A Novel Nonhormonal Treatment for Vasomotor Symptoms
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
Essential Reads: Folic Acid, Neural Tube Defects, and Congenital Heart Defects
Despite the unequivocal benefits of folic acid supplementation and recommendations urging all women of reproductive age to take folic acid supplements, preconceptual use of folic acid has not increased substantially.
Essential Reads: Breastfeeding and Anti-Epileptic Drugs
While data are limited regarding AEDs and breastfeeding, it appears that none of the AEDs are excreted at high levels into the breast milk, nor have they been associated with high rates of adverse events in the nursing infant.
Moving Backwards? Why Doesn’t the Canadian Task Force on Preventive Health Care Recommend Standardized Screening for Perinatal Depression?
This task force does not recommend universal, instrument-based screening for perinatal depression because we lack clear evidence that screening improves outcomes.